Alnylam Pharmaceuticals (NASDAQ:ALNY): 8 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $119.38 in Alnylam Pharmaceuticals (NASDAQ:ALNY). However, the stock price could fluctuate by $ 32.61 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $180 price target with the lower price estimate is calculated at $81
Many analysts have stated their opinion on the company shares. Leerink Swann maintains its view on Alnylam Pharmaceuticals (NASDAQ:ALNY) according to the research report released by the firm to its investors. The shares have now been rated Outperform by the stock experts at the ratings house. Leerink Swann lowers the price target from $120 per share to $107 per share on Alnylam Pharmaceuticals . The rating by the firm was issued on May 3, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director officer (Chief Executive Officer) of Alnylam Pharmaceuticals, Inc., Maraganore John had sold 30,151 shares worth of $2,046,348 in a transaction dated April 19, 2016. In this transaction, 30,151 shares were sold at $67.87 per share.
Alnylam Pharmaceuticals (NASDAQ:ALNY) stock ended Monday session in the red zone in a volatile trading. The stock closed down 2.52 points or 3.99% at $60.65 with 1,182,457 shares getting traded. Post opening the session at $62.54, the shares hit an intraday low of $60.39 and an intraday high of $63.19 and the price was in this range throughout the day. The company has a market cap of $5,189 million and the number of outstanding shares have been calculated to be 85,560,535 shares. The 52-week high of Alnylam Pharmaceuticals (NASDAQ:ALNY) is $140 and the 52-week low is $49.96.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.